Every DEF 14A that Profusa, Inc. (PFSA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PFSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFSA filings page.
Profusa, Inc. (PFSA) is calling a virtual special stockholders’ meeting on September 18, 2026 to vote on two proposals. The main item would authorize the Board, at its discretion, to implement one or more reverse stock splits of the common stock, at ratios ranging from 1-for-2 to 1-for-12 in total, at any time up to September 18, 2028, without further stockholder approval. As of the August 19, 2026 record date, 605,647 shares of common stock were outstanding.
The Board cites continued listing on Nasdaq’s Capital Market, including compliance with the $1.00 minimum bid price, improved liquidity, and better access to financing (including shelf and equity-line facilities) as key reasons for this authority. The company discloses multiple prior reverse splits in 2026 (including a 1-for-4 split on August 17, 2026) used in efforts to satisfy Nasdaq requirements and notes that failure to maintain listing could severely limit liquidity and capital-raising options. A secondary proposal would permit adjournment of the meeting to solicit more proxies if needed.
Profusa, Inc. is asking stockholders to approve several major proposals at its June 23, 2026 virtual annual meeting. The board seeks to elect Lauren Chung to a three-year term and obtain broad authority to execute one or more reverse stock splits in a 1‑for‑5 to 1‑for‑200 range through June 23, 2028 to help regain Nasdaq bid‑price compliance.
Stockholders are also being asked to approve issuing $30,000,000 of non‑voting convertible preferred stock to Bio Insights LLC for PanOmics Assay assets, which will convert into common shares and carry a 3% royalty on related revenue and a board nomination right. Another proposal would allow conversion of a $1,869,796 promissory note into common stock above the 19.99% Nasdaq threshold, and an equity plan amendment would raise the 2025 plan reserve from 100,386 to 795,930 shares (15% of 4,510,268 shares outstanding after the reverse split). An adjournment proposal would let the company delay the meeting to gather more proxies if needed.
Profusa, Inc. is calling a virtual special meeting on January 27, 2026 to ask stockholders to approve a broad reverse stock split authority, ratify its auditor, and allow a possible meeting adjournment if needed to gather more votes.
The reverse stock split proposal would let the board, any time through January 27, 2028, combine the company’s common shares at a ratio between 1‑for‑30 and 1‑for‑200, with total splits over time capped at 1‑for‑200. As of the December 23, 2025 record date, Profusa had 86,414,296 common shares outstanding.
The company explains it is out of compliance with Nasdaq’s $1.00 minimum bid price and certain market value requirements, and views the reverse split as a tool to raise the share price to help regain and maintain listing. Stockholders are also being asked to ratify CBIZ CPAs P.C. as independent auditor for the year ending December 31, 2025, and to approve the ability to adjourn the meeting briefly to solicit additional proxies if Proposals One or Two lack sufficient support.